SINCE THE ADVENT of thyroid analogues, clinical studies have shown a definite cholesterol-lowering effect with dosages that do not cause an appreciable calorigenic effect. However, to date, only an occasional reference has been made to therapeutic success in patients with xanthomatosis given thyroid analogues. The dietary approach to hypercholesteremic xanthomatosis has been reviewed and detailed elsewhere.
It is not my intent to enter the controversy on the value of maintaining a normal level of serum cholesterol in relation to development of atherosclerosis. Rather, this study reports the use of 3,5,3' triiodothyropropionic acid (Triopron) over a 2†-year period in a patient with primary hypercholesteremia with tuberous and disseminated xanthomatosis.
During the past 10 years many diverse scientific disciplines have collaborated to produce alterations of the thyroxin molecule, resulting in various analogues, and to study their physiological effects on animals and man. Definite dissociation of function by changes in the structure of